Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Smoothelin-like protein 2 (SMTNL2)
- Target
- SMTNL2
- Molecular classification
- Other (Cytoskeletal regulatory protein), Calponin homology (CH) domain protein, Filamentous actin-associated protein
01
Overview
Smoothelin-like protein 2 is a cytoskeletal regulatory protein highly expressed in skeletal muscle and epithelial tissues, involved in actin filament organization and stabilization of the apical cortex[1][3][4][6]. It contains a calponin homology domain and binds actin directly, modulating turnover in part via inhibition of coronin-1B[1][3][4]. SMTNL2 is a substrate of MAP kinases such as JNK1-3 and ERK2, being phosphorylated at specific sites critical for its function during muscle differentiation and epithelial morphogenesis[2][1]. Expression is developmentally regulated and concentrated at sites of junctional and apical actin in epithelia and during myocyte differentiation[3][4]. There are no validated therapeutic drugs or biomarker applications at present; the molecule is primarily of research interest in cellular cytoskeleton regulation and morphogenesis[1][2][3][4][6].
- Other names
- Smoothelin-like 2SMTNL2FLJ42461SMTL2_HUMAN (UniProt)Smoothelin-like protein 2
02
Biological functions
Actin cytoskeleton organizationApical cortex maturation in epithelial cellsModeration of actin turnoverInhibition of coronin-1BMicrotubule organizing center participationSubstrate and regulator within MAP kinase (JNK, ERK) signaling pathways
03
Disease associations
Other (no direct roles in cancer, cardiovascular, or infectious disease reported; potential relevance in muscle differentiation and morphogenesis)
Beyond the preview
Go deeper on Smoothelin-like protein 2 (SMTNL2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Smoothelin-like protein 2 (SMTNL2).